a:5:{s:8:"template";s:5073:" {{ keyword }}
{{ text }}
";s:4:"text";s:12828:" Vous êtes authentifié. Sur quel site souhaitez-vous vous connecter ? En s'appuyant sur sa plateforme propriétaire ERYCAPS®, une nouvelle technologie permettant l'encapsulation de médicaments dans les globules rouges, ERYTECH Pharma développe un portefeuille de produits candidats ciblant des marchés avec d'importants besoins médicaux non satisfaits. contenue, ni les analyses qui y sont exprimées ne sauraient engager la responsabilité BOURSORAMA. contactez-nous. Les opinions ou estimations qui y sont exprimées sont celles de leurs auteurs In addition, the COVID-19 pandemic and the associated containment efforts have had a serious adverse impact on the economy, the severity and duration of which are uncertain. Preliminary findings of the study suggest that eryaspase achieved the target level and duration of asparaginase activity in these patients. Une question ? Une étude de phase II parrainée par des chercheurs sur la leucémie lymphoblastique aiguë est en cours dans les pays nordiques d'Europe. Eryaspase is in Phase 3 clinical development for the treatment of second-line pancreatic cancer and in Phase 2 for the treatment of first-line triple-negative breast cancer. Vous pourrez alors de nouveau accéder à votre compte membre. Reporting of final data from the NOPHO trial is expected by the end of 2020.Financial Results for the First Half of 2020 * Key financial figures for the first half of 2020 compared with the same period of the previous year are summarized below: In thousands of euros 1H 2020 (6 months)1H 2019 (6 months) Revenues  —  —  Other income 1,849 2,965  Total operating income 1,849 2,965  Research and development (28,846)(22,718) General and administrative (8,372)(10,493) Total operating expenses (37,218)(33,210) Total operating loss (35,369)(30,245) Financial income 672 1,265  Financial expenses (265)(305) Financial income, net 407 960  Loss before tax (34,962)(29,285) Income tax - (1) Net loss (34,962)(29,286) * Net loss for the first half of 2020 was €35.0 million, up €5.7 million (+19%) year-over-year, with a €5.1 million increase (+17%) in operating loss and a €0.6 million decrease in financial income. Due to COVID-19-related challenges with data cleaning, the actual reporting of the interim results is expected in the first quarter of 2021. There can be no guarantees with respect to pipeline product candidates that the candidates will receive the necessary regulatory approvals or that they will prove to be commercially successful. Given these uncertainties, no representations are made as to the accuracy or fairness of such forward-looking statements, forecasts and estimates. ni garantie d'aucune sorte. Furthermore, forward-looking statements, forecasts and estimates only speak as of the date of this press release. The Phase 2 trial of eryaspase in acute lymphoblastic leukemia (ALL) patients who developed hypersensitivity to pegylated asparaginase, sponsored by the Nordic Organization of Pediatric Hematology and Oncology (NOPHO), completed target enrollment in June 2020. (2)   Without treasury shares. The Company has put measures in place to facilitate trial conduct during the COVID-19 pandemic and continues to expect to complete enrollment in the fourth quarter of 2020. All rights reserved. The ATM program can be used once the shelf registration statement is declared effective by the SEC, and will be available for the Company’s use until September 21, 2023, unless terminated prior to such date in accordance with the sales agreement or the maximum number of ADSs to be sold thereunder has been reached. Vous allez recevoir un email à l'adresse indiquée lorsque vous aviez créé votre compte. About Erytech Pharma SA Erytech Pharma S.A. operates as a biopharmaceutical company. En espérant "qu'elle" continue de grimper même sans volumes... A l'ouverture US ................................... Les PP vendent quand il faut acheter et achètent quand il faut vendre !!! Rejoignez le forum ERYTECH PHARMA : partagez vos avis et analyses boursières, échangez sur l'actualité de ERYTECH PHARMA ERYP Euronext Paris sur Boursorama A PDF accompanying this release is available at: http://ml.globenewswire.com/Resource/Download/c3b898f1-a97b-4042-bb4b-c925860dd69d. * Volume échangé sur la journée comparé au nombre de titres en circulation, Cotation temps réel In April 2020, the U.S. Food and Drug Administration (FDA) granted eryaspase Fast Track Designation as a potential second-line treatment of patients with metastatic pancreatic cancer. ERYTECH disclaims any obligation to update any such forward-looking statement, forecast or estimates to reflect any change in ERYTECH’s expectations with regard thereto, or any change in events, conditions or circumstances on which any such statement, forecast or estimate is based, except to the extent required by law. The €5.1 million increase in operating loss was attributable to the €6.1 million increase in preclinical and clinical development expenses, mostly related to expenses for the Company’s Phase 3 clinical trial in pancreatic cancer, the €2.1 million decrease in general and administrative expenses, of which €2.3 million was related to the end of manufacturing capacity expenses mostly incurred in 2019, and the €1.1 million decrease in income, of which €0.9 million consisted in the upfront payment from the June 2019 license agreement with SQZ Biotechnologies that did not recur in 2020. With the closing of a convertible debt financing, complemented with the recent establishment of an ATM facility, we have put financing alternatives in place that can allow us to extend our cash horizon until the end of the third quarter of next year, beyond the expected upcoming data read-outs.”Business Highlights * TRYbeCA-1, the pivotal Phase 3 clinical trial evaluating ERYTECH’s lead product candidate, eryaspase, in second-line metastatic pancreatic cancer, has randomized more than 450 of the approximately 500 patients to be enrolled in the trial. Currency in EUR, Man Who Predicted Rise of AMZN Has New Prediction. Since June, trial enrollment in TRYbeCA-1 has resumed at pre-COVID-19 levels, and more than 90% of patients have been enrolled in the trial. PEA-PME, 4.970 ERYTECH PHARMA EST UNE SOCIÉTÉ BIOPHARMACEUTIQUE DE STADE CLINIQUE QUI DÉVELOPPE DES THÉRAPIES INNOVANTES BASÉES SUR LES GLOBULES ROUGES POUR LUTTER CONTRE DES CANCERS ET DES MALADIES ORPHELINES. €, Vos portefeuilles boursiers en temps réel, Agenda / Communiqués / BALO / OST / Rapports annuels. The extent and duration of the impact on the Company’s business and operations is highly uncertain, and that impact includes effects on its clinical trial operations and supply chain. To date, the Company has called two tranches under the convertible bond financing agreement, not reflected in the Company’s cash position at the end of June, and € 5.6 million of notes have been converted into 1,039,475 new shares, representing 5.5% of the Company’s outstanding share capital as of the date of last issuance. A new shelf registration statement on Form F-3 was filed by the Company with the U.S. Securities and Exchange Commission (the “SEC”) on September 21, 2020 to roll over the Company’s previously filed shelf registration and to cover the ATM program. Devenez membre, Nouveau sur Boursorama ? Leveraging its proprietary ERYCAPS® platform, which uses a novel technology to encapsulate drug substances inside red blood cells, ERYTECH is developing a pipeline of product candidates for patients with high unmet medical needs. The €27.7 million decrease in cash position during the first 6 months of 2020, consisting of €14.6 million in the first quarter of 2020 and €13.1 million in the second quarter, was the result of a €28.1 million net cash utilization and was mostly comprised of a €29.2 million net cash utilization in operating activities, €1.1 million used for investing activities and €2.2 million generated in financing activities, while the appreciation in the period of the U.S. dollar against the euro led to a €0.4 million favorable currency exchange impact. Additionally, the addition of eryaspase to the combination chemotherapy was associated with an acceptable tolerability profile, enabling the majority of these patients to receive their fully intended courses of asparginase. PEA Votre objectif de cours pour le 29 septembre.... ligne financement at the market de 30M$ maxi, RDB >> Eryp faiblement valorisé face à une thérapeutique, Politique de protection des données membres. Cliquez ensuite sur le lien présent dans le mail. ERYTECH plans to further discuss these data with FDA to determine the potential next steps and to assess the path forward for eryaspase in this setting. erytech pharma est une sociÉtÉ biopharmaceutique de stade clinique qui dÉveloppe des thÉrapies innovantes basÉes sur les globules rouges pour lutter contre des cancers et des maladies orphelines. Ak avant retrait de la côte, idem que txcell? The pandemic could have a material adverse impact on the Company’s business, operations and financial results for an extended period of time.CONTACTS ERYTECH                      Eric Soyer CFO & COOLifeSci Advisors, LLC Investor Relations Corey Davis, Ph.D. NewCap Mathilde Bohin / Louis-Victor Delouvrier Investor relations Nicolas Merigeau Media relations     +33 4 78 74 44 38 investors@ERYTECH.com +1 (212) 915 - 2577 cdavis@lifesciadvisors.com+33 1 44 71 94 94 ERYTECH@newcap.eu PDF available at: http://ml.globenewswire.com/Resource/Download/aef35ccc-a397-4801-afa0-fb052f23445a, Discover new investment ideas by accessing unbiased, in-depth investment research, Paris - Paris Delayed Price. ERYTECH is part of the CAC Healthcare, CAC Pharma & Bio, CAC Mid & Small, CAC All Tradable, EnterNext PEA-PME 150 and Next Biotech indexes. Nous chargeons votre espace membre. Government stabilization efforts will only partially mitigate the consequences. Les informations * On June 24, 2020, ERYTECH signed an agreement with Alpha Blue Ocean and European High Growth Opportunities Securitization Fund (the Investors) for the issuance of zero-coupon convertible notes with share warrants attached whereby the Investors committed to subscribe for up to a maximum of €60 million in the event of conversion of all the notes, subject to the regulatory limit of 20% dilution, unless further authorized. In accordance with article 223-11 of general regulation of Autorité des Marchés Financiers, this number is calculated on the basis of all shares carrying the single and double voting rights, including shares without voting rights. Connectez-vous pour ajouter ERYTECH PHARMA à The NOPHO trial is now fully enrolled with 55 patients treated and we are expecting full data to be available before the end of the year. Certain of these statements, forecasts and estimates can be recognized by the use of words such as, without limitation, “believes”, “anticipates”, “expects”, “intends”,“plans”, “seeks”, “estimates”, “may”, “will” and “continue” and similar expressions. Therefore, actual results and timeline may turn out to be materially different from the anticipated future results, performance or achievements expressed or implied by such statements, forecasts and estimates. ERYTECH’s primary focus is on the development of product candidates that target the altered metabolism of cancer cells by depriving them of amino acids necessary for their growth and survival.The Company’s lead product candidate, eryaspase, which consists of L-asparaginase encapsulated inside donor-derived red blood cells, targets the cancer cells’ altered asparagine and glutamine metabolism. par les membres qui en sont émetteurs. For more information, please visit www.erytech.com        Forward-looking information This press release contains forward-looking statements including but not limited to statements with respect to the clinical development plans of eryaspase; the clinical trials of the Company’s product candidates, including the timeline for patient enrollment as well as expected timing of the availability of results and interim superiority analysis; potential impacts of the ongoing coronavirus (COVID-19) pandemic on the Company’s clinical trials, including TRYbeCA-1 clinical trial; the possible sales of ADSs pursuant to the ATM program; and the Company’s anticipated cash runway as extended by its convertible bond financing and ATM facility. ";s:7:"keyword";s:14:"erytech pharma";s:5:"links";s:811:"Avenir Font Family Github, 4 Bedroom Dog Trot House Plans, Pembroke Garden Centre, Clipsal Classic, Dallas Morning News Voter Recommendations, Mc Bloodbound, Collin County Voting 2020, ";s:7:"expired";i:-1;}